[ad_1]
DTaP and dca market
summary
Pertussis vaccine is used for whooping cough. This vaccine is only available in combination with other vaccines. Vaccination against whooping cough is recommended for all children, babies, adolescents and pregnant women. Diphtheria, tetanus and pertussis (DTaP) vaccines are given to children under the age of seven, while tetanus, diphtheria and pertussis (Tdap) vaccines are given to older children and adults. Immunizing children is one of the safest and most cost-effective ways to create an environment free of whooping cough.
Browse more detailed information about the report at https://www.reportsmonitor.com/request_sample/95204
The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) recommend that all children be vaccinated against whooping cough. According to the WHO in 2015, about 86% of infants received three doses of diphtheria, tetanus and pertussis (DTP3) vaccine worldwide to protect them from infectious diseases. In 2015, UNICEF procurement of DTwP vaccines reached 5.8 million doses in 18 countries and territories, of which four countries, such as Egypt, Morocco, Uzbekistan and Zimbabwe accounted for more than 80% of the total. total purchases from UNICEF.
The main players in the DTaP and Tdap market are: Sanofi Pasteur, GlaxoSmithKline, Protein Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp., Astellas Pharma US, Inc., Pfizer Inc., Johnson & Johnson, Institute of Biological Products Co., Ltd., AstraZeneca, Emergent BioSolutions Inc.
The main regions play a vital role in the DTaP and dca market North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia, etc.)), Middle East and Africa (Egypt, Saudi Arabia, Egypt, Nigeria, South Africa and United Arab Emirates)
Check discount for this report @ https://www.reportsmonitor.com/check_discount/95204
Research Framework
Factors such as high birth rates, increasing numbers of seniors, government initiatives, increasing uptake of pertussis vaccine, and government insurance and reimbursement scenarios should stimulate the global pertussis vaccine market. According to the WHO, in 2015, 126 countries had reached at least 90% coverage of the vaccine against diphtheria, tetanus and whooping cough. On the other hand, factors such as vaccine injuries and adverse events are expected to hinder the growth of the global pertussis vaccine market. In the United States, in 2015, 7 claims under the federal Vaccine Injury Compensation Program (VICP) had been filed for injuries and deaths as a result of pertussis vaccination, including three deaths and four deaths. serious injuries.
The pertussis vaccines market was segmented by product type, vaccine type, age group, end-user and geographic region. In terms of product type, the pertussis vaccine market is clbadified in DTaP and Tdap vaccines. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel and Quaracel. T
The Tdap vaccine segment includes products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is clbadified as a whole cell vaccine and acellular vaccine. The acellular vaccine segment is heavily used because of the reduction of side effects. The acellular vaccine has an efficacy of about 71% to 85%, while the whole cell vaccine is about 78%. In terms of age group, the pertussis vaccine market is clbadified in the adult and pediatric categories. In terms of end-user, the market is clbadified in hospitals, clinics and vaccination centers. Geographically, the skeletal vaccine market is clbadified in North America, Latin America, Europe, Asia-Pacific, the Middle East and Africa.
North America dominates the pertussis vaccine market due to an increase in the number of geriatric patients and an increase in pertussis mortality in the United States, the engine of the pertussis vaccine market. In 2014, according to the CDC, 28,660 pertussis cases were reported in the United States. The North American market is followed by the markets of Europe and Asia-Pacific. The Asia Pacific is expected to grow faster due to rapid population growth, the increasing adoption of vaccines and the increased prevalence of infectious diseases. These factors should fuel the market for pertussis vaccines.
In the Asia-Pacific region, Thailand accounts for 99% of pertussis vaccination coverage, followed by Japan and China with 98% and 97%, respectively. It is estimated that developing countries such as Brazil, South Africa and Mexico offer growth to the pertussis vaccine market, which is due to increased public and private hedging, rising health care costs and awareness.
Scope of the report:
The world market for DTaP and dca: Type Outlook: DTaP, Td, Tdap.
The world market for DTaP and dca: Outlook application: Adult, pediatric.
Reasons to buy:
– Consider the composition of the DTaP and TdapMarket, according to the different applications of (name of the market), highlighting the resources and the major actors of the sector.
– Examine the pipeline of products and study by stage of the disease, the target molecule, with granulated breakdown of key symptoms.
– Understand growth in (market name) and market income for the global market and among the major players and market segments.
– Study the market in terms of revenue from generic and premium products.
– Determine business opportunities in the DTaP and TdapMarket sales scenario by badyzing trends in authorization and co-development.
Read the detailed report @ https://www.reportsmonitor.com/report/95204/DTaP-and-Tdap-Vaccines-Market
Thank you for reading this article. you can also get a report version of chapter wise or individual region like Asia, USA, Europe.
Publish views:
1
Source link
